ARQT News and Press, Arcutis Biotherapeutics Inc. From 07/02/21

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “A key debate on Arcutis’ lead asset, topical roflumilast, has been on its market potential given the likely difficult formul...

Arcutis Biotherapeutics (ARQT) down 5.5% premarket after announcing its decision to terminate the Phase 2a clinical trial evaluating ARQ-252, a topical small molecule inhibitor of Janus kinase type 1, as a potential treatment for vitiligo (ARQ-252-213).The decision is based on furth...

Formulation-related observations from ARQ-252 trial in chronic hand eczema informed early termination of Phase 2a ARQ-252 trial in vitiligo Company progressing new formulation with goal of greater drug delivery to targets in the skin WESTLAKE VILLAGE, Calif., July 01, 2021 (GL...

Mario13/E+ via Getty Images Altimmune draws lower price targets on Wall Street after setback Altimmune (ALT) has extended the post-market losses in early hours today with a ~30.3% loss in the pre-market after the company announced an end to its AdCOVID COVID-19 vaccine developm...

WESTLAKE VILLAGE, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-...

Arcutis Biotherapeutics (ARQT) announces that Sue-Jean Lin has been appointed to the company's board of directors, effective June 9, 2021.The company also announces that Jonathan Silverstein has decided to step down from the board citing personal reasons.Lin is S...

WESTLAKE VILLAGE, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-...

WESTLAKE VILLAGE, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-derm...

Data show roflumilast produced robust efficacy compared to vehicle in both Phase 3 studies on the primary efficacy endpoint of IGA success at eight weeks Roflumilast also demonstrated statistically significant improvements over vehicle in the key secondary endpoints of I-IGA s...

Arcutis Biotherapeutics (ARQT): Q1 GAAP EPS of -$0.76 beats by $0.26.Cash, cash equivalents, restricted cash and marketable securities of $446.5MPress Release For further details see: Arcutis Biotherapeutics EPS beats by $0.26